Strategy and implementation of a publicly listed US-based biotech in Europe

Situation

• Our client, an innovative publicly listed US biotech with a strong pipeline in anti-infectives, required support in the strategic development and implementation of an Entry in Europe strategy for its lead product
• Our client needed a tailor-made strategy to optimize its co-marketing agreement in Europe

Bionest Contribution

• Bionest's pan-European team (France, UK, Germany) supported our client for a two year period:

1. Analysis of strategic options and competitive benchmarking
2. Organizational blueprint including salesforce sizing, HQ location and full financial forecasting
3. Scenario modeling
4. Constitution of European commercial advisory board
5. Implementation support via network of preferred partners (recruitment, accountancy etc.)

Key Results

• Our client was able to develop and implement a detailed pre-launch plan for its product on time and on budget
• Establishment of European bridgehead for the launch of subsequent pipeline products